한글목차

SVT-15473(0.05%)는 백내장 수술과 관련된 염증과 통증을 치료하기 위해 프로피온산 클로베타졸을 눈에 직접 투여하는 수중 유형 제제입니다. 또한 독자적인 IMPACT-SVT 기술로 나노에멀젼으로 제형화되어 1회량 바이알에 충전되어 있기 때문에 시판되고 있는 다른 대체품보다 우수한 이점을 가지고 있습니다. 다른 많은 부신 피질 스테로이드와는 달리 안압을 상승시키지 않는 것으로 나타났습니다.

향후 몇 년동안 세계의 광범위한 조사와 의료비 증가로 수술 후 통증 시장 시나리오가 변화할 것입니다. 개발, 과제 평가, SVT-15473의 이점 영향을 미칠 수 있는 기회를 모색하고 있습니다.술 후 통증에 대한 다른 신흥 제품이 SVT-15473에 엄격한 시장 경쟁을 줄 것으로 예상되며, 가까운 미래에 후발 신흥 치료제의 발매가 시장에 큰 영향을 미칠 것으로 보입니다.

이 보고서는 주요 7개국에서 SVT-15473 시장을 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술후 통증에 있어서의 SVT-15473의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 SVT-15473 시장 평가

• 수술 후 통증에서 SVT-15473 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"SVT-15473 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about SVT-15473 for Postoperative pain in the seven major markets. A detailed picture of the SVT-15473 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SVT-15473 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SVT-15473 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%) is a new therapeutic entity (NTE) for the treatment of inflammation and pain that occurs after ocular surgery is an oil in a water solution that delivers the drug clobetasol propionate directly into the eye to treat inflammation and pain associated with cataract surgery. This technology promotes anti-inflammatory genes by binding to glucocorticoid receptors. Moreover, its formulation as a nanoemulsion with its proprietary IMPACT-SVT technology and its presentation in single-dose vials offers superior advantages over other alternatives on the market. In addition to its efficacy and safety, clinical trials have shown that, unlike many other corticosteroids, it does not increase intraocular pressure.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SVT-15473 description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on SVT-15473 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SVT-15473 research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around SVT-15473.
• The report contains forecasted sales of SVT-15473 for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for SVT-15473 in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SVT-15473 Analytical Perspective by DelveInsight

• In-depth SVT-15473 Market Assessment

This report provides a detailed market assessment of SVT-15473 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• SVT-15473 Clinical Assessment

The report provides the clinical trials information of SVT-15473 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SVT-15473 dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to SVT-15473 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SVT-15473 in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of SVT-15473 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SVT-15473 in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SVT-15473?
• What is the clinical trial status of the study related to SVT-15473 in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SVT-15473 development?
• What are the key designations that have been granted to SVT-15473 for Postoperative pain?
• What is the forecasted market scenario of SVT-15473 for Postoperative pain?
• What are the forecasted sales of SVT-15473 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SVT-15473 for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. SVT-15473 Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SVT-15473 Market Assessment

• 5.1. Market Outlook of SVT-15473 in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of SVT-15473 in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SVT-15473 in the United States for Postoperative pain
  • 5.3.2. Market Size of SVT-15473 in Germany for Postoperative pain
  • 5.3.3. Market Size of SVT-15473 in France for Postoperative pain
  • 5.3.4. Market Size of SVT-15473 in Italy for Postoperative pain
  • 5.3.5. Market Size of SVT-15473 in Spain for Postoperative pain
  • 5.3.6. Market Size of SVT-15473 in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of SVT-15473 in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options